Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Shares of small biotech Arcutis Biotherapeutics (ARQT) have surged nearly three times in market value in the past year.The upside has been primarily driven by the positive regulatory updates regarding the company’s efforts to expand the label of its only marketed product, Zoryve.This drug is currently approved for use in different formulations – as foam and cream – across different indications.ARQT Stock PerformanceIn the past year, Arcutis’ stock has skyrocketed over 272% against the industry’s 14.1% fall. ...